Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...

Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

新泽西州拉威 - 全球医疗保健公司Merck & Co., Inc. (NYSE:MRK)今日宣布,其GARDASIL®9 HPV疫苗的三期临床试验在16至26岁日本男性中达到主要和次要终点。与安慰剂相比,该疫苗在减少九种HPV类型引起的持续性肛门生殖器感染方面显示出疗效。 这项名为V503-064的试验共招募了1,059名参与者,旨在减少HPV 6、11、16、18、31、33、45、52和58 ...

The Pan American Health Organisation has launched a partnership with Merck & Company to improve health care and maternal health outcomes for women ...